Hi Mark,
Quote:
That's not what I said (sorry). I just quoted the AFFIRM Tysabri monotherapy trial results, which found a relative risk reduction of disability progression of about 43% but an absolute risk reduction of 12% (29% placebo vs. 17% on Tysabri, or a difference of 12%).
|
Sorry for the lack of recollection memory
Your comparison, IMHO, vs placebo improvement even makes Tysabri less of the blockbuster that Biogen has been preaching.
I still have a "feeling" that there are going to be some unexpected problems with the user group of this drug once the numbers start to increase.
Harry